The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Alessenko A.V.

Institute of Biochemical Physic of the Russian Academy of Sciences

Gutner U.A.

Institute of Biochemical Physic of the Russian Academy of Sciences

Nebogatikov V.O.

Institute of Physiologically Active Compounds of the Russian Academy of Sciences

Shupik M.A.

Institute of Biochemical Physic of the Russian Academy of Sciences

Ustyugov A.A.

Institute of Physiologically Active Compounds of the Russian Academy of Sciences

The role of sphingolipids in pathogenesis of amyotrophic lateral sclerosis

Authors:

Alessenko A.V., Gutner U.A., Nebogatikov V.O., Shupik M.A., Ustyugov A.A.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(8): 131‑140

DOI: 10.17116/jnevro2021121081131

Read: 4958 times

Download PDF (RU)
Contact the author
Table of contents

THE ROLE OF SPHINGOLIPIDS IN PATHOGENESIS OF AMYOTROPHIC LATERAL SCLEROSIS
THE ROLE OF SPHINGOLIPIDS IN PATHOGENESIS OF AMYOTROPHIC LATERAL SCLEROSIS

To cite this article:

Alessenko AV, Gutner UA, Nebogatikov VO, Shupik MA, Ustyugov AA. The role of sphingolipids in pathogenesis of amyotrophic lateral sclerosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(8):131‑140. (In Russ.)
https://doi.org/10.17116/jnevro2021121081131

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Oculomotor diso­rders in patients with amyotrophic late­ral scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4):7-12
Sporadic form of Guam disease (ALS—parkinsonism—dementia complex). S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7):135-141
Combination of amyotrophic late­ral scle­rosis with Alzheimer’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2026;(1):132-136
Lipid profile indi­cators and their ratios in patients with non-ST elevation acute coro­nary syndrome. Russian Cardiology Bulletin. 2025;(3):48-53
Oppo­rtunities of combination therapy for chro­nic liver diseases: resu­lts of the multicenter PROMETHEUS study. Russian Journal of Evidence-Based Gastroenterology. 2025;(3):56-68
Comprehensive asse­ssment of students’ health based on the resu­lts of examinations at the health center. Russian Journal of Preventive Medi­cine. 2025;(12):76-82
Abstract:

Amyotrophic lateral sclerosis (ALS) is an incurable neurodegenerative disease characterized by selective degeneration of motor neurons of the spinal cord and motor cortex and brain stem. The key features of the course of this disease are excitotoxicity, oxidative stress, mitochondrial dysfunction, neuro-inflammatory and immune reactions. Recently, the mechanisms of programmed cell death (apoptosis), which may be responsible for the degeneration of motor neurons in this disease, have been intensively studied. In this regard, sphingolipids, which are the most important sources of secondary messengers that transmit cell proliferation, differentiation and apoptosis signals, and are involved in the development of neuroinflammatory and immune responses, are of particular interest in the context of ALS pathogenesis. The review provides information from domestic and foreign authors on the involvement of various sphingolipids (sphingomyelins, ceramides, sphingosine, sphinganin, sphingosine-1-phosphate, galactosylceramides, glucosylceramides, gangliosides) in the development of pro-inflammatory reactions and apoptosis of motor neurons in ALS. The authors discuss the prospects of using new drugs that control the metabolism of sphingolipids for the treatment of ALS.

Keywords:

side amyotrophic sclerosis (SAS)
BAS models
lipids
fatty acids
phospholipids
cholesterol
sphingolipids

Authors:

Alessenko A.V.

Institute of Biochemical Physic of the Russian Academy of Sciences

Gutner U.A.

Institute of Biochemical Physic of the Russian Academy of Sciences

Nebogatikov V.O.

Institute of Physiologically Active Compounds of the Russian Academy of Sciences

Shupik M.A.

Institute of Biochemical Physic of the Russian Academy of Sciences

Ustyugov A.A.

Institute of Physiologically Active Compounds of the Russian Academy of Sciences

Received:

11.11.2019

Accepted:

14.03.2021

Close metadata

References:

  1. Van Den Bosch L. Genetic rodent models of amyotrophic lateral sclerosis. J Biomed Biotechnol. 2011;2011:348765. https://doi.org/10.1155/2011/348765
  2. Ghasemi M, Brown RH. Genetics of amyotrophic lateral sclerosis. Cold Spring Harb Perspect Med. 2017;7:a024125. https://doi.org/10.1101/cshperspect.a024125
  3. Robberecht W, Van Den Bosch L. Excitotoxicity and Amyotrophic Lateral Sclerosis. Neurodegener Dis. 2005;2(3-4):147-159.  https://doi.org/10.1159/000089620
  4. Greco V, Longone P, Spalloni A, Pieroni L, Urbani A. Crosstalk Between Oxidative Stress and Mitochondrial Damage: Focus on Amyotrophic Lateral Sclerosis. Adv Exp Med Biol. 2019;1158:71-82.  https://doi.org/10.1007/978-981-13-8367-0_5
  5. Shi P, Gal J, Kwinter DM, Liu X, Zhu H. Mitochondrial dysfunction in amyotrophic lateral sclerosis. Biochim Biophys Acta. 2010;1802(1):45-51.  https://doi.org/10.1016/j.bbadis.2009.08.012
  6. McCombe PA, Henderson RD. The Role of Immune and Inflammatory Mechanisms in ALS. Curr Mol Med. 2011;11(3):246-254.  https://doi.org/10.2174/1566211213754895240
  7. Hensley K, Floyd RA, Gordon B, Mou S, Pye QN, Stewart C, West M, Williamson K. Temporal patterns of cytokine and apoptosis-related gene expression in spinal cords of the G93A-SOD1 mouse model of amyotrophic lateral sclerosis. J Neurochem. 2002;82:365-367.  https://doi.org/10.1046/j.1471-4159.2002.00968.x
  8. Ekegren T, Grundström E, Lindholm D, Aquilonius SM. Upregulation of Bax protein and increased DNA degradation in ALS spinal cord motor neurons. Acta Neurol Scand. 1999;100:317-321.  https://doi.org/10.1111/j.1600-0404.1999.tb00403.x
  9. Guégan C, Vila M, Rosoklija G, Hays AP, Przedborski S. Recruitment of the mitochondrial-dependent apoptotic pathway in amyotrophic lateral sclerosis. J Neurosci. 2001;21:6569-6576. https://doi.org/10.1523/JNEUROSCI.21-17-06569.2001
  10. Hussain G, Anwar H, Rasul A, Imran A, Qasim M, Zafar S, Imran M, Kamran SKS, Aziz N, Razzaq A, Ahmad W, Shabbir A, Iqbal J, Baig SM, Ali M, Gonzalez de Aguilar JL, Sun T, Muhammad A, Muhammad Umair A. Lipids as biomarkers of brain disorders. Crit Rev Food Sci Nut. 2019;7:1-24.  https://doi.org/10.1080/10408398.2018.1529653
  11. Hussain G, Wang J, Rasul A, Anwar H, Imran A, Qasim M, Zafar S, Kamran SKS, Razzaq A, Aziz N, Ahmad W, Shabbir A, Iqbal J. Role of cholesterol and sphingolipids in brain development and neurological diseases. Lipids Health Dis. 2019;18:26-38.  https://doi.org/10.1186/s12944-019-0965-z
  12. Dupuis L, Corcia P, Fergani A, Gonzalez De Aguilar JL, Bonnefont-Rousselot D, Bittar R, Seilhean D, Hauw JJ, Lacomblez L, Loeffler JP, Meininger V. Dyslipidemia is a protective factor in amyotrophic lateral sclerosis. Neurology. 2008;70:1004-1009. https://doi.org/10.1212/01.wnl.0000285080.70324.27
  13. Chen X, Yazdani S, Piehl F, Magnusson PKE, Fang F. Polygenic link between blood lipids and amyotrophic lateral sclerosis. Neurobiol Aging. 2018;67:202.e1-202.e6.  https://doi.org/10.1016/j.neurobiolaging.2018.03.022
  14. Alessenko AV. The potential role for sphingolipids in neuropathogenesis of Alzheimer’s disease. Biochemistry (Moscow) Supplement Series B: Biomedical Chemistry. 2013;59:25-50. (In Russ.). https://doi.org/10.1016/j.neurobiolaging.2018.03.022
  15. Alessenko AV, Gurianova SV. Potential role of ceramides in neurodegenerative diseases. In book Sphingomyelin and Ceramides: Occurance, Biosynthesis and Role in Diseases NOVA Sci. Publisher NY, USA, Ed. C. Watkins; 2015;21-53. 
  16. Dodge JC. Lipid Involvement in Neurodegenerative Diseases of the Motor System: Insights from Lysosomal Storage Diseases. Front Mol Neurosci. 2017;10:356.  https://doi.org/10.3389/fnmol.2017.00356
  17. Abbott SK, Li H, Muñoz SS, Knoch B, Batterham M, Murphy KE, Halliday GM, Garner B Altered ceramide acyl chain length and ceramide synthase gene expression in Parkinson’s disease. Mov Disord. 2014;4:518-526.  https://doi.org/10.1002/mds.25729
  18. Pujol-Lereis LM. Alteration of Sphingolipids in Biofluids: Implications for Neurodegenerative Diseases. Int J Mol Sci. 2019;20:e3564. https://doi.org/10.3390/ijms20143564
  19. Murugesan V, Chuang WL, Liu J, Lischuk A, Kacena K, Lin H, Pastores GM, Yang R, Keutzer J, Zhang K, Mistry PK. Glucosylsphingosine is a key biomarker of Gaucher disease. Am J Hematol. 2016;91(11):1082-1089. https://doi.org/10.1002/ajh.24491
  20. Blasco H, Veyrat-Durebex C, Bocca C, Patin F, Vourc’h P, Kouassi Nzoughet J, Lenaers G, Andres CR, Simard G, Corcia P, Reynier P. Lipidomics Reveals Cerebrospinal-Fluid Signatures of ALS. Sci Rep. 2017;7(1):17652. https://doi.org/10.1038/s41598-017-17389-9
  21. Agira T, Jarvis WD, Yu RK. Role of sphingolipid-mediated cell death in neurodegenerative diseases. J Lipid Res. 1998;39:1-16. 
  22. Hannun YA, Obeid LM. Principles of bioactive lipid signalling: lessons from sphingolipids. Nat Rev Mol Cell Biol. 2008;12(8):139-150.  https://doi.org/10.1038/nrm2329
  23. Zhang K, Haynes T-AS, Filippova M, Filippov V. Quantification of ceramide levels in mammalian cells by high performance liquid chromatography coupled to tandem mass spectrometry with multiple-reaction-monitoring mode (HPLC-MS/MS-MRM). Analytical Methods. 2011;3:1193-1197. https://doi.org/10.1039/c1ay05022b
  24. Gault CR, Obeid LM, Hannun YA. An overview of sphingolipid metabolism: from synthesis to breakdown. Adv Exp Med Biol. 2010;688:1-23.  https://doi.org/10.1007/978-1-4419-6741-1_1
  25. Mullen TD, Hannun YA, Obeid LM. Ceramide synthases at the centre of sphingolipid metabolism and biology. Biochem J. 2012;441:789-802.  https://doi.org/10.1042/bj20111626
  26. Horres CR, Hannun YA. The roles of neutral sphingomyelinases in neurological pathologies. Neurochem Res. 2012;37:1137-1149. https://doi.org/10.1007/s11064-011-0692-y
  27. Duan RD. Alkaline sphingomyelinase: an old enzyme with novel implications. Biochim Biophys Acta. 2006;1761:281-291.  https://doi.org/10.1016/j.bbalip.2006.03.007
  28. Hofmann K, Tomiuk S, Wolff G, Stoffel W. Cloning and characterization of the mammalian brain-specific, Mg2+-dependent neutral sphingomyelinase. Proc Natl Acad Sci USA. 2000;97:5895-5900. https://doi.org/10.1073/pnas.97.11.5895
  29. Taffese FG, Huitema K, Hermansson M, van der Poel S, van den Dikkenberg J, Uphoff A, Somerharju P, Holthuis JC. Both sphingomyelin synthases SMS1 and SMS2 are required for sphingomyelin homeostasis and growth in human HeLa cells. J Biol Chem. 2007;282:17537-17547. https://doi.org/10.1074/jbc.m702423200
  30. Mao C, Obeid LV. Ceramidases: regulators of cellular responses mediated by ceramide, sphingosine, and sphingosine-1-phosphate. Biochim Biophys Acta. 2008;1781:424-434.  https://doi.org/10.1016/j.bbalip.2008.06.002
  31. Maceyka M, Harikumar KB, Milstein S, Spiegel S. Sphingosine-1-phosphate signaling and its role in disease. Trends Cell Biol. 2012;22:50-60.  https://doi.org/10.1016/j.tcb.2011.09.003
  32. Maceyka M, Sankala H, Hait NC, Le Stunff H, Liu H, Toman R, Collier C, Zhang M, Satin LS, Merrill AH Jr, Milstien S, Spiegel S. SphK1 and SphK2, sphingosine kinase isoenzymes with opposing functions in sphingolipid metabolism. J Biol Chem. 2005;280(44):37118-37129. https://doi.org/10.1074/jbc.m502207200
  33. Czubowicz K, Jęśko H, Wencel P, Lukiw WJ, Strosznajder RP. The Role of Ceramide and Sphingosine-1-Phosphate in Alzheimer’s disease and Other Neurodegenerative Disorders. Mol Neurobiol. 2019;56(8):5436-5455. https://doi.org/10.1007/s12035-018-1448-3
  34. Paul P, Kamisaka Y, Marks DL, Pagano RE. Purification and characterization of UDP-glucose: ceramide glucosyltransferase from rat liver Golgi membranes. J Biol Chem. 1996;271:2287-2293. https://doi.org/10.1074/jbc.271.4.2287
  35. Palestini P, Masserini M, Fiorilli A, Calappi E, Tettamanti G. 1 Age-related changes in the ceramide composition of the major gangliosides present in rat brain subcellular fractions enriched in plasma membranes of neuronal and myelin origin. J Neurochemistry. 1993;61:955-960.  https://doi.org/10.1111/j.1471-4159.1993.tb03608.x
  36. Denny CA, Desplats PA, Thomas EA. Seyfried TN. Cerebellar lipid differences between R6/1 transgenic mice and humans with Huntington’s disease. J Neurochem. 2010;115(3):748-758.  https://doi.org/10.1111/j.1471-4159.2010.06964.x
  37. Alessenko AV, Bugrova AE, Dudnik LB. Connection of lipid peroxide oxidation with the sphingomyelin pathway in the development of Alzheimer’s disease. Biochem Soc Trans. 2004;32(Pt1):144-146.  https://doi.org/10.1042/bst0320144
  38. Brodowicz J, Przegaliński E, Müller CP, Filip M. Ceramide and Its Related Neurochemical Networks as Targets for Some Brain Disorder Therapies. Neurotox Res. 2018;33(2):474-484.  https://doi.org/10.1007/s12640-017-9798-6
  39. Dodge JC, Treleaven CM, Pacheco J, Cooper, S., Bao C, Abraham M, Cromwell M, Sardi SP, Chuang WL, Sidman RL, Cheng SH, Shihabuddin LS. Glycosphingolipids are modulators of disease pathogenesis in amyotrophic lateral sclerosis. Proc Nat. Acad Sci USA. 2015;112:8100-8105. https://doi.org/10.1042/bst0320144
  40. Hannun YA, Obeid LM. Many ceramides. J Biol Chem. 2011;286(32):27855-27862. https://doi.org/10.1074/jbc.R111.254359
  41. Dawkins JL, Hulme DJ, Brahmbhatt SB, Auer-Grumbach M, Nicholson GA. Mutations in SPTLC1, encoding serine palmitoyltransferase, long chain base subunit-1, cause hereditary sensory neuropathy type I. Nat Genet. 2001;27(3):309-312.  https://doi.org/10.1038/85879
  42. Krebs S, Medugorac I, Röther S, Strässer K, Förster M. A missense mutation in the 3-ketodihydrosphingosine reductase FVT1 as candidate causal mutation for bovine spinal muscular atrophy. Proc Natl Acad Sci USA. 2007;104(16):6746-6751. https://doi.org/10.1073/pnas.0607721104
  43. Zhou J, Tawk M, Tiziano FD, Veillet J, Bayes M, Nolent F, Garcia V, Servidei S, Bertini E, Castro-Giner F, Renda Y, Carpentier S, Andrieu-Abadie N, Gut I, Levade T, Topaloglu H, Melki J. Spinal muscular atrophy associated with progressive myoclonic epilepsy is caused by mutations in ASAH1. Am J Hum Genet. 2012;91(1):5-14.  https://doi.org/10.1016/j.ajhg.2012.05.001
  44. Cutler RG, Pedersen WA, Camandola S, Rothstein JD, Mattson MP. Evidence that accumulation of ceramides and cholesterol esters mediates oxidative stress-induced death of motor neurons in amyotrophic lateral sclerosis. Ann Neurol. 2002;52(4):448-457.  https://doi.org/10.1002/ana.10312
  45. Kirby J, Ning K, Ferraiuolo L, Heath PR, Ismail A, Kuo SW, Valori CF, Cox L, Sharrack B, Wharton SB, Ince PG, Shaw PJ, Azzouz M. Phosphatase and tensin homologue/protein kinase B pathway linked to motor neuron survival in human superoxide dismutase 1-related amyotrophic lateral sclerosis. Brain. 2011;134(Pt2):506-517.  https://doi.org/10.1093/brain/awq345
  46. Pehar M, Cassina P, Vargas MR, Castellanos R, Viera L, Beckman JS, Estevez AG, Barbeito L. Astrocytic production of nerve growth factor in motor neuron apoptosis: implications for amyotrophic lateral sclerosis. J Neurochem. 2004;89:464-473.  https://doi.org/10.1111/j.1471-4159.2004.02357.x
  47. Alessenko AV, Khrenov AV. Role of sphingosine in induced apoptosis. Lipids. 1999;34:75-76.  https://doi.org/10.1007/bf02562235
  48. Tamiya-Koizumi K, Murate T, Suzuki M, Simbulan CM, Nakagawa M, Takemura M, Furuta K, Izuta S, Yoshida S. Inhibition of DNA primase by sphigosine and its analogues paralleles with their growth suppression of cultured human leukemic cells. Biochem Mol Biol Int. 1997;41:1179-1189. https://doi.org/10.1080/15216549700202271
  49. Koiv A, Palvimo J, Kinnunen PK. Evidence for ternary complex formation by histone H1 and liposomes. Biochemistry. 1995;34:8018-8027. https://doi.org/10.1021/bi00025a007
  50. Taha TA, Mullen ND, Obeid LM. A house divided: ceramide, sphingosine, and sphingosine-1-phosphate in programmed cell death. Biochim Biophys Acta. 2006;1758:2027-2036. https://doi.org/10.1016/j.bbamem.2006.10.018
  51. Rohrbach T, Maceyka M, Spiegel S. Sphingosine kinase and sphingosine-1-phosphate in liver pathobiology. Crit Rev Biochem Mol Biol. 2017;52(5):543-553.  https://doi.org/10.1080/10409238.2017.1337706
  52. Gutner UA, Shupik MA, Maloshitskaya OA, Sokolov SA, Rezvykh AP, Funikov SYu, Lebedev AT, Ustyugov AA, Alesenko AV. Changes in metabolism of sphingoid bases in the brain and spinal cord of transgenic mice fus(1-359) modeling amyotrophic lateral sclerosis. Biochemistry. 2019;84:1437-1449. (In Russ.).
  53. Chatterjee S, Pandey A. The Yin and Yang of lactosylceramide metabolism: Implications in cell function. Biochim Biophys Acta. 2008;1780(3):370-382.  https://doi.org/10.1016/j.bbagen.2007.08.010
  54. Won JS, Singh AK, Singh I. Lactosylceramide: A lipid second messenger in neuroinflammatory disease. J Neurochem. 2007;103(suppl 1):180-191.  https://doi.org/10.1111/j.1471-4159.2007.04822.x
  55. Frakes AE, Ferraiuolo L, Haidet-Phillips AM, Schmelzer L, Braun L, Miranda CJ, Ladner KJ, Bevan AK, Foust KD, Godbout JP, Popovich PG, Guttridge DC, Kaspar BK. Microglia induce motor neuron death via the classical NF-κB pathway in amyotrophic lateral sclerosis. Neuron. 2014;81(5):1009-1023. https://doi.org/10.1016/j.neuron.2014.01.013
  56. Zhuang S, Kong L, Li C, Chen L, Zhang T. GALC mutations in Chinese patients with late-onset Krabbe disease: a case report. BMC Neurol. 2019;19(1):122.  https://doi.org/10.1186/s12883-019-1345-z
  57. Henriques A, Croixmarie V, Priestman DA, Rosenbohm A, Dirrig-Grosch S, D’Ambra E, Huebecker M, Hussain G, Boursier-Neyret C, Echaniz-Laguna A, Ludolph AC, Platt FM, Walther B, Spedding M, Loeffler JP, Gonzalez De Aguilar JL. Amyotrophic lateral sclerosis and denervation alter sphingolipids and up-regulate glucosylceramide synthase. Hum Mol Genet. 2015;24(25):7390-7405. https://doi.org/10.1093/hmg/ddv439
  58. Ishibashi Y, Kohyama-Koganeya A, Hirabayashi Y. New insights on glucosylated lipids: metabolism and functions. Biochim Biophys Acta. 2013;1831:1475-1485. https://doi.org/10.1016/j.bbalip.2013.06.001
  59. Kohyama-Koganeya A, Sasamura T, Oshima E, Suzuki E, Nishihara S, Ueda R, Hirabayashi Y. Drosophila glucosylceramide synthase: a negative regulator of cell death mediated by proapoptotic factors. J Biol Chem. 2004;279(34):35995-36002. https://doi.org/10.1074/jbc.M400444200
  60. Henriques A, Huebecker M, Blasco H, Keime C, Andres CR, Corcia P, David A. Priestman DA, Platt FM, Spedding M, and Loeffleret J-P. Inhibition of β-glucocerebrosidase activity preserves motor unit integrity in a mouse model of amyotrophic lateral sclerosis. Sci Rep. 2017;7(1):5235. https://doi.org/10.1038/s41598-017-05313-0
  61. Inokuchi J. Neurotrophic and neuroprotective actions of an enhancer of ganglioside biosynthesis. Int Rev Neurobiol. 2009;85:319-336.  https://doi.org/10.1016/s0074-7742(09)85022-8
  62. Dawson G, Stefansson K. Gangliosides of human spinal cord: Aberrant composition of cords from patients with amyotrophic lateral sclerosis. J Neurosci Res. 1984;12(2-3):213-220.  https://doi.org/10.1002/jnr.490120209
  63. Salazar-Grueso EF, Routbort MJ, Martin J, Dawson G, Roos RP. Polyclonal IgM anti-GM1 ganglioside antibody in patients with motor neuron disease and variants. Ann Neurol. 1990;27(5):558-563.  https://doi.org/10.1002/ana.410270517
  64. Stevens A, Weller M, Wiethölter H. A characteristic ganglioside antibody pattern in the CSF of patients with amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 1993;56(4):361-364.  https://doi.org/10.1136/jnnp.56.4.361
  65. Rapport MM, Donnenfeld H, Brunner W, Hungund B, Bartfeld H. Ganglioside patterns in amyotrophic lateral sclerosis brain regions. Ann Neurol. 1985;18(1):60-67.  https://doi.org/10.1002/ana.410180111
  66. Yim SH, Farrer RG, Hammer JA, Yavin E, Quarles RH. Differentiation of oligodendrocytes cultured from developing rat brain is enhanced by exogenous GM3 ganglioside. J Neurosci Res. 1994;38(3):268-281.  https://doi.org/10.1002/jnr.490380305
  67. Ferraiuolo L, Meyer K, Sherwood TW, Vick J, Likhite S, Frakes A, Miranda CJ, Braun L, Heath PR, Pineda R, Beattie CE, Shaw PJ, Askwith CC, McTigue D, Kaspar BK. Oligodendrocytes contribute to motor neuron death in ALS via SOD1-dependent mechanism. Proc Natl Acad Sci USA. 2016;113(42):e6496-e6505. https://doi.org/10.1073/pnas.1607496113
  68. Olsen MK, Roberds SL, Ellerbrock BR, Fleck TJ, McKinley DK, Gurney ME. Disease mechanisms revealed by transcription profiling in SOD1-G93A transgenic mouse spinal cord. Ann Neurol. 2001;50(6):730-740.  https://doi.org/10.1002/ana.1252
  69. Lobsiger CS, Boillée S, Cleveland DW. Toxicity from different SOD1 mutants dysregulates the complement system and the neuronal regenerative response in ALS motor neurons. Proc Natl Acad Sci USA. 2007;104(18):7319-7326. https://doi.org/10.1073/pnas.0702230104
  70. Baker DJ, Blackburn DJ, Keatinge M, Sokhi D, Viskaitis P, Heath PR, Ferraiuolo L, Kirby J, Shaw PJ. Lysosomal and phagocytic activity is increased in astrocytes during disease progression in the SOD1 (G93A) mouse model of amyotrophic lateral sclerosis. Front Cell Neurosci. 2015;9:410.  https://doi.org/10.3389/fncel.2015.00410
  71. Barenholz Y. Sphingomyelin and cholesterol: from membrane biophysics and rafts to potential medical applications. Subcell Biochem. 2004;37:167-215.  https://doi.org/10.1007/978-1-4757-5806-1_5
  72. Megha, London E. Ceramide selectively displaces cholesterol from ordered lipid domains (rafts): implications for lipid raft structure and function. J Biol Chem. 2004;279(11):9997-10004. https://doi.org/10.1074/jbc.m309992200
  73. Slotte JP, Bierman EL. Depletion of plasma-membrane sphingomyelin rapidly alters the distribution of cholesterol between plasma membranes and intracellular cholesterol pools in cultured fibroblasts. Biochem J. 1988;250:653-658.  https://doi.org/10.1042/bj2500653
  74. Marmillot P, Patel S, Lakshman MR. Reverse cholesterol transport is regulated by varying fatty acyl chain saturation and sphingomyelin content in reconstituted high density lipoproteins. Metabolism. 2007;56(2):251-259.  https://doi.org/10.1016/j.metabol.2006.09.021
  75. Stranahan AM, Cutler RG, Button C, Telljohann R, Mattson MP Diet-induced elevations in serum cholesterol are associated with alterations in hippocampal lipid metabolism and increased oxidative stress. J Neurochem. 2011;118:611-615.  https://doi.org/10.1111/j.1471-4159.2011.07351.x
  76. Stein O, Ben-Naim M, Dabach Y, Hollander G, Stein Y. Modulation of sphingomyelinase-induced cholesterol esterification in fibroblasts, CaCo2 cells, macrophages and smooth muscle cells. Biochim Biophys Acta. 1992;1126(3):291-297.  https://doi.org/10.1016/0005-2760(92)90243-o
  77. Härmälä AS, Pörn MI, Slotte JP. Sphingosine inhibits sphingomyelinase-induced cholesteryl ester formation in cultured fibroblasts. Biochim Biophys Acta. 1993;1210(1):97-104.  https://doi.org/10.1016/0005-2760(93)90054-d
  78. Henriques A, Croixmarie V, Bouscary A, Mosbach A, Keime C, Boursier-Neyret C, Walter B, Spedding M, Loeffler JP. Sphingolipid Metabolism Is Dysregulated at Transcriptomic and Metabolic Levels in the Spinal Cord of an Animal Model of Amyotrophic Lateral Sclerosis. Front Mol Neurosci. 2018;10:433.  https://doi.org/10.3389/fnmol.2017.00433
  79. Chitnis T, Weiner H.L. CNS inflammation and neurodegeneration. J Clin Invest. 2017;127(10):3577-3587. https://doi.org/10.1172/JCI90609
  80. Alexianu ME, Kozovska M, Appel SH. Immune reactivity in a mouse model of familial ALS correlates with disease progression. Neurology. 2001;57:1282-1289. https://doi.org/10.1212/WNL.57.7.1282
  81. Malaspina A, Puentes F, Amor S. Disease origin and progression in amyotrophic lateral sclerosis: an immunology perspective. International Immunology. 2015;27:117-129.  https://doi.org/10.1093/intimm/dxu099
  82. Mantovani S, Garbelli S, Pasini A, Alimonti D, Perotti C, Melazzini M, Bendotti C, Mora G. Immune system alterations in sporadic amyotrophic lateral sclerosis patients suggest an ongoing neuroinflammatory process. J Neuroimmunology. 2009;210:73-79.  https://doi.org/10.1016/j.jneuroim.2009.02.012
  83. Turner MR, Cagnin A, Turkheimer FE, Miller CC, Shaw CE, Brooks DJ, Leigh PN, Banati RB. Evidence of widespread cerebral microglial activation in amyotrophic lateral sclerosis: an [11C] (R)-PK11195 positron emission tomography study. Neurobiol Dis. 2004;15(3):601-609.  https://doi.org/10.2174/1381612823666170316124500
  84. Potenza RL, De Simone R, Armida M, Mazziotti V, Pèzzola A, Popoli P, Minghetti L. Fingolimod: A Disease-Modifier Drug in a Mouse Model of Amyotrophic Lateral Sclerosis. Neurotherapeutics. 2016;13(4):918-927.  https://doi.org/10.1007/s13311-016-0462-2
  85. Hooten KG, Beers DR, Zhao W, Appel SH. Protective and Toxic Neuroinflammation in Amyotrophic Lateral Sclerosis. Neurotherapeutics. 2015;12(2):364-375.  https://doi.org/10.1007/s13311-014-0329-3
  86. Appel SH, Stewart SS, Appel V. A double-blind study of the effectiveness of cyclosporine in amyotrophic lateral sclerosis. Arch Neurol. 1988;45(4):381-386.  https://doi.org/10.1001/archneur.1988.00520280027011
  87. Drachman DB, Chaudhry V, Cornblath D, Kuncl RW, Pestronk A, Clawson L, Mellits ED, Quaskey S, Quinn T, Calkins A, Order S. Trial of immunosuppression in amyotrophic lateral sclerosis using total lymphoid irradiation. Ann Neurol. 1994;35(2):142-150.  https://doi.org/10.1002/ana.410350205
  88. Meucci N, Nobile-Orazio E, Scarlato G. Intravenous immunoglobulin therapy in amyotrophic lateral sclerosis. J Neurol. 1996;243(2):117-120.  https://doi.org/10.1007/bf02444000
  89. Berry JD, Paganoni S, Atassi N, Macklin EA, Goyal N, Rivner M, Simpson E, Appel S, Grasso DL, Mejia NI, Mateen F, Gill A, Vieira F, Tassinari V, Perrin S. Phase IIa trial of fingolimod for amyotrophic lateral sclerosis demonstrates acceptable acute safety and tolerability. Muscle Nerve. 2017;56(6):1077-1084. https://doi.org/10.1002/mus.25733
  90. Hunter SF, Bowen JD, Reder AT. The direct effects of fingolimod in the central nervous system: implications for relapsing multiple sclerosis. CNS Drugs. 2016;30:135-147.  https://doi.org/10.1007/s40263-015-0297-0
  91. Hannun YA, Loomis CR, Merrill AH Jr, Bell RM. Sphingosine inhibition of protein kinase C activity and of phorbol dibutyrate binding in vitro and in human platelets. J Biol Chem. 1986;261:12604-12609. https://www.jbc.org/content/261/27/12604.long
  92. Bartke N, Hannun YA. Bioactive sphingolipids: metabolism and function. J Lipid Res. 2009;50(suppl):91-96.  https://doi.org/10.1194/jlr.R800080-JLR200
  93. O’Sullivan S, Dev KK. Sphingosine-1-phosphate receptor therapies: advances in clinical trials for CNS-related diseases. Neuropharmacology. 2017;113(PtB):597-607.  https://doi.org/10.1016/j.neuropharm.2016.11.006
  94. Pinschewer DD, Ochsenbein AF, Odermatt B, Brinkmann V, Hengartner H, Zinkernagel RM. FTY720 immunosuppression impairs effector T cell peripheral homing without affecting induction, expansion, and memory. J Immunol. 2000;164(11):5761-5770. https://doi.org/10.4049/jimmunol.164.11.5761
  95. Kahan BD. FTY720: from bench to bedside. Transplant Proc. 2004; 36(suppl 2):531-543.  https://doi.org/10.1016/j.transproceed.2004.01.092
  96. Serpero LD, Filaci G, Parodi A, Battaglia F, Kalli F, Brogi D, Mancardi GL, Uccelli A, Fenoglio D. Fingolimod modulates peripheral effector and regulatory T cells in MS patients. J Neuroimmune Pharmacol. 2013;8(5):1106-1113. https://doi.org/10.1007/s11481-013-9465-5
  97. Anastasiadou S, Knöll B. The multiple sclerosis drug fingolimod (FTY720) stimulates neuronal gene expression, axonal growth and regeneration. Exp Neurol. 2016;279:243-260.  https://doi.org/10.1016/j.expneurol.2016.03.012
  98. Henkel JC, Beers DR, Wen S. Regulatory T-lymphocytes mediate amyotrophic lateral sclerosis progression and survival. EMBO Mol Med. 2013;5(2):64-79.  https://doi.org/10.1002/emmm.201201544
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.